Comparison of Low-Dose Rivaroxaban and Low Molecular Weight Heparin Calcium in Patients with Acute Pulmonary Embolism
Objective:To explore difference in efficacy between low-dose rivaroxaban and low molecular weight heparin calcium in the treatment of patients with acute pulmonary embolism.Methods:A total of 120 patients with acute pulmonary embolism treated in a hospital from February in 2021 to February in 2022 were selected.According to the random number table method,they were divided into low-dose rivaroxaban group(group A)and low molecular weight heparin calcium group(group B),with 60 cases in each group.After admission,all patients were administrated conventional symptomatic treatment.Group A was administrated oral rivaroxaban tablets on the basis of conventional symptomatic treatment,group B was administrated subcutaneous injection of low molecular weight heparin calcium injection on the basis of conventional symptomatic treatment,and both groups were treated continuously for 3 months.The clinical efficacy,coagulation function indexes[activated partial thromboplastin time(APTT),fibrinogen(FIB)and prothrombin time(PT)],lung function indexes[forced vital capacity as a percentage of the predicted value(FVC%pred),forced expiratory volume in one second(FEV1)and its percentage of the predicted value(FEV1%pred)],arterial blood gas analysis indexes[arterial partial pressure of oxygen(PaO2),arterial partial pressure of carbon dioxide(PaCO2)]and adverse reactions were compared between the two groups.Results:After treatment,the total effective rate of group A(86.67%)was higher than that of group B(70.00%,P<0.05).The levels of APTT and PT were elevated in both groups(P<0.05),and those in group A were higher than those in group B(P<0.05).The level of FIB was decreased in both groups(P<0.05),and that in group A was lower than that in group B(P<0.05).The FVC%pred,FEV1 and FEV1%pred were increased in both groups(P<0.05),and those in group A were higher than those in group B(P<0.05).PaO2 and PaCO2 were improved in both groups(P<0.05),with more significant improvement in group A(P<0.05).The overall incidence of adverse reactions in group A(6.67%)was lower than that in group B(26.67%,P<0.05).Conclusion:Low-dose rivaroxaban and low molecular weight heparin calcium can effectively improve coagulation and lung function in patients with acute pulmonary embolism,and the clinical efficacy of low-dose rivaroxaban is better than that of low molecular weight heparin calcium,with a lower incidence of adverse reactions in patients.
国家科技期刊平台
NSTL
万方数据
